Switch theme
Sign up to access all valuation multiples
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
2015
1K+
LTM Revenue $135M
LTM EBITDA -$1.0B
$771M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
GRAIL has a last 12-month revenue (LTM) of $135M and a last 12-month EBITDA of -$1.0B.
In the most recent fiscal year, GRAIL achieved revenue of $126M and an EBITDA of -$610M.
GRAIL expects next 12-month revenue of XXX and NTM EBITDA of XXX
See GRAIL valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $135M | XXX | $126M | XXX | XXX | XXX |
| Gross Profit | -$54.2M | XXX | -$78.0M | XXX | XXX | XXX |
| Gross Margin | -40% | XXX | -62% | XXX | XXX | XXX |
| EBITDA | -$1.0B | XXX | -$610M | XXX | XXX | XXX |
| EBITDA Margin | -770% | XXX | -486% | XXX | XXX | XXX |
| EBIT | -$1.2B | XXX | -$768M | XXX | XXX | XXX |
| EBIT Margin | -892% | XXX | -612% | XXX | XXX | XXX |
| Net Profit | -$1.4B | XXX | -$2.0B | XXX | XXX | XXX |
| Net Margin | -1058% | XXX | -1614% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, GRAIL's stock price is $38.
GRAIL has current market cap of $1.4B, and EV of $771M.
See GRAIL trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $771M | $1.4B | XXX | XXX | XXX | XXX | $-43.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, GRAIL has market cap of $1.4B and EV of $771M.
GRAIL's trades at 6.1x EV/Revenue multiple, and -1.3x EV/EBITDA.
Equity research analysts estimate GRAIL's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
GRAIL has a P/E ratio of -1.0x.
See valuation multiples for GRAIL and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV (current) | $771M | XXX | $771M | XXX | XXX | XXX |
| EV/Revenue | 5.7x | XXX | 6.1x | XXX | XXX | XXX |
| EV/EBITDA | -0.7x | XXX | -1.3x | XXX | XXX | XXX |
| EV/EBIT | -0.6x | XXX | -1.0x | XXX | XXX | XXX |
| EV/Gross Profit | -14.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.0x | XXX | -0.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGRAIL's last 12 month revenue growth is 18%
GRAIL's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.7M for the same period.
GRAIL's rule of 40 is -668% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
GRAIL's rule of X is -726% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for GRAIL and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Margin | -770% | XXX | -486% | XXX | XXX | XXX |
| EBITDA Growth | -67% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -668% | XXX | -468% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -726% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 123% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 257% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 550% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GRAIL acquired XXX companies to date.
Last acquisition by GRAIL was XXXXXXXX, XXXXX XXXXX XXXXXX . GRAIL acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was GRAIL founded? | GRAIL was founded in 2015. |
| Where is GRAIL headquartered? | GRAIL is headquartered in United States of America. |
| How many employees does GRAIL have? | As of today, GRAIL has 1K+ employees. |
| Who is the CEO of GRAIL? | GRAIL's CEO is Mr. Robert Ragusa. |
| Is GRAIL publicy listed? | Yes, GRAIL is a public company listed on NAS. |
| What is the stock symbol of GRAIL? | GRAIL trades under GRAL ticker. |
| When did GRAIL go public? | GRAIL went public in 2024. |
| Who are competitors of GRAIL? | Similar companies to GRAIL include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of GRAIL? | GRAIL's current market cap is $1.4B |
| What is the current revenue of GRAIL? | GRAIL's last 12 months revenue is $135M. |
| What is the current revenue growth of GRAIL? | GRAIL revenue growth (NTM/LTM) is 18%. |
| What is the current EV/Revenue multiple of GRAIL? | Current revenue multiple of GRAIL is 5.7x. |
| Is GRAIL profitable? | Yes, GRAIL is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of GRAIL? | GRAIL's last 12 months EBITDA is -$1.0B. |
| What is GRAIL's EBITDA margin? | GRAIL's last 12 months EBITDA margin is -770%. |
| What is the current EV/EBITDA multiple of GRAIL? | Current EBITDA multiple of GRAIL is -0.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
